TEXAS VIRTUAL MPN WORKSHOP: Module III
Myelofibrosis
Presentations
To JAKi or not to JAKi How I treat ”Early” MF
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
27 August, 2020
Ruxolitinib in 2020 and Beyond: The good, the suboptimal, and the failure
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH
27 August, 2020
Fedratinib
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK
27 August, 2020
Pacritinib
John Mascarenhas, MD, Mount Sinai, New York, NY
27 August, 2020
Momelotinib, Clinical Experience
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS
27 August, 2020
